Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2013 Dec 5;34(2):331–337. doi: 10.1161/ATVBAHA.113.302586

Figure 5. Genetic reduction of VEGFR2 expression rescues aberrant angiogenesis in epsin deleted mice.

Figure 5

A, Representative wound injuries at 0 and 9 days in WT, EC-iDKO or EC-iDKO-Flkfl/+ mice. B, Wound areas from A were calculated and reported as a wound healing curve. C, CD31 immunostaining of wounds from A isolated at day 9. D, WT or EC-iDKO mice were injected with STZ, followed by wound injury as described in A. E, Representative matrigel plugs (supplemented with or without 200 ng/mL VEGF-A) isolated 5 days post s.c. injection into WT, EC-iDKO or EC-iDKO-Flkfl/+ mice. F, CD31 immunostaining of matrigel plugs from E. G, Representative WT, EC-iDKO or EC-iDKO-Flkfl/+ LLC tumors harvested at 15 days. H, Quantification of tumor volumes in G. I, CD31 immunostaining of tumors from G. J, Quantification of CD31immunostaining in I using SlideBook software. B, D, H and J, error bars indicate the mean ± s.e.m. n > 5, *p < 0.05. Scale bars: A, 1 mm; C, F, and I, 50 μm.